158 related articles for article (PubMed ID: 29683100)
1. Pioglitazone Therapy and Fractures: Systematic Review and Meta- Analysis.
Pavlova V; Filipova E; Uzunova K; Kalinov K; Vekov T
Endocr Metab Immune Disord Drug Targets; 2018; 18(5):502-507. PubMed ID: 29683100
[TBL] [Abstract][Full Text] [Related]
2. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis.
Loke YK; Singh S; Furberg CD
CMAJ; 2009 Jan; 180(1):32-9. PubMed ID: 19073651
[TBL] [Abstract][Full Text] [Related]
3. Thiazolidinedione use and the risk of fractures.
Toulis KA; Goulis DG; Anastasilakis AD
CMAJ; 2009 Apr; 180(8):841-2; author reply 842-3. PubMed ID: 19364796
[No Abstract] [Full Text] [Related]
4. Thiazolidinediones: do harms outweigh benefits?
Lipscombe LL
CMAJ; 2009 Jan; 180(1):16-7. PubMed ID: 19073650
[No Abstract] [Full Text] [Related]
5. Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis.
Liao HW; Saver JL; Wu YL; Chen TH; Lee M; Ovbiagele B
BMJ Open; 2017 Jan; 7(1):e013927. PubMed ID: 28057658
[TBL] [Abstract][Full Text] [Related]
6. Fracture risk associated with common medications used in treating type 2 diabetes mellitus.
Wolverton D; Blair MM
Am J Health Syst Pharm; 2017 Aug; 74(15):1143-1151. PubMed ID: 28743778
[TBL] [Abstract][Full Text] [Related]
7. Pioglitazone and PPAR-γ modulating treatment in hypertensive and type 2 diabetic patients after ischemic stroke: a national cohort study.
Liu CH; Lee TH; Lin YS; Sung PS; Wei YC; Li YR
Cardiovasc Diabetol; 2020 Jan; 19(1):2. PubMed ID: 31910836
[TBL] [Abstract][Full Text] [Related]
8. Thiazolidinediones and fractures: evidence from translating research into action for diabetes.
Bilik D; McEwen LN; Brown MB; Pomeroy NE; Kim C; Asao K; Crosson JC; Duru OK; Ferrara A; Hsiao VC; Karter AJ; Lee PG; Marrero DG; Selby JV; Subramanian U; Herman WH
J Clin Endocrinol Metab; 2010 Oct; 95(10):4560-5. PubMed ID: 20631021
[TBL] [Abstract][Full Text] [Related]
9. The risk of fractures associated with thiazolidinediones: a self-controlled case-series study.
Douglas IJ; Evans SJ; Pocock S; Smeeth L
PLoS Med; 2009 Sep; 6(9):e1000154. PubMed ID: 19787025
[TBL] [Abstract][Full Text] [Related]
10. The risk of sudden cardiac arrest and ventricular arrhythmia with rosiglitazone versus pioglitazone: real-world evidence on thiazolidinedione safety.
Leonard CE; Brensinger CM; Dawwas GK; Deo R; Bilker WB; Soprano SE; Dhopeshwarkar N; Flory JH; Bloomgarden ZT; Gagne JJ; Aquilante CL; Kimmel SE; Hennessy S
Cardiovasc Diabetol; 2020 Feb; 19(1):25. PubMed ID: 32098624
[TBL] [Abstract][Full Text] [Related]
11. Pioglitazone for primary stroke prevention in Asian patients with type 2 diabetes and cardiovascular risk factors: a retrospective study.
Hung YC; Chiu LT; Huang HY; Bau DT
Cardiovasc Diabetol; 2020 Jun; 19(1):94. PubMed ID: 32563247
[TBL] [Abstract][Full Text] [Related]
12. Adding pioglitazone to insulin containing regimens in type 2 diabetes: systematic review and meta-analysis.
Clar C; Royle P; Waugh N
PLoS One; 2009 Jul; 4(7):e6112. PubMed ID: 19568428
[TBL] [Abstract][Full Text] [Related]
13. Effect of pioglitazone in acute ischemic stroke patients with diabetes mellitus: a nested case-control study.
Woo MH; Lee HS; Kim J
Cardiovasc Diabetol; 2019 May; 18(1):67. PubMed ID: 31151454
[TBL] [Abstract][Full Text] [Related]
14. Effects of Anti-Diabetic Drugs on Fracture Risk: A Systematic Review and Network Meta-Analysis.
Zhang YS; Zheng YD; Yuan Y; Chen SC; Xie BC
Front Endocrinol (Lausanne); 2021; 12():735824. PubMed ID: 34721294
[TBL] [Abstract][Full Text] [Related]
15. Management of bone fragility in type 2 diabetes: Perspective from an interdisciplinary expert panel.
Chiodini I; Gaudio A; Palermo A; Napoli N; Vescini F; Falchetti A; Merlotti D; Eller-Vainicher C; Carnevale V; Scillitani A; Pugliese G; Rendina D; Salcuni A; Bertoldo F; Gonnelli S; Nuti R; Toscano V; Triggiani V; Cenci S; Gennari L
Nutr Metab Cardiovasc Dis; 2021 Jul; 31(8):2210-2233. PubMed ID: 34059385
[TBL] [Abstract][Full Text] [Related]
16. A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus.
Chilcott J; Tappenden P; Jones ML; Wight JP
Clin Ther; 2001 Nov; 23(11):1792-823; discussion 1791. PubMed ID: 11768834
[TBL] [Abstract][Full Text] [Related]
17. Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes.
Aubert RE; Herrera V; Chen W; Haffner SM; Pendergrass M
Diabetes Obes Metab; 2010 Aug; 12(8):716-21. PubMed ID: 20590749
[TBL] [Abstract][Full Text] [Related]
18. Pioglitazone for type 2 diabetes mellitus.
Richter B; Bandeira-Echtler E; Bergerhoff K; Clar C; Ebrahim SH
Cochrane Database Syst Rev; 2006 Oct; 2006(4):CD006060. PubMed ID: 17054272
[TBL] [Abstract][Full Text] [Related]
19. Pioglitazone use associated with reduced risk of the first attack of ischemic stroke in patients with newly onset type 2 diabetes: a nationwide nested case-control study.
Ha J; Choi DW; Kim KY; Nam CM; Kim E
Cardiovasc Diabetol; 2021 Jul; 20(1):152. PubMed ID: 34315501
[TBL] [Abstract][Full Text] [Related]
20. Thiazolidinediones: the Forgotten Diabetes Medications.
Lebovitz HE
Curr Diab Rep; 2019 Nov; 19(12):151. PubMed ID: 31776781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
